限局性前立腺癌に対するI-125密封小線源永久挿入療法単独治療後の直腸出血の検討

Risk factors for rectal bleeding associated with I-125 brachytherapy for localized prostate cancer

我が国の前立腺癌罹患率は上昇傾向にある。男性の部位別年齢調整罹患率は，2000年まで胃癌，肺癌，結腸癌，肝臓癌，直腸癌に次いで第6位であったが，2003年以降は胃癌，肺癌に次いで第3位となり，国立がん研究センター『がん統計予測』では，2020年には男性の第1位になるとされた^1）。

The purpose of this study is to evaluate the risk factors for rectal bleeding associated with I-125 brachytherapy. We retrospectively analyzed 199 patients who were treated with I-125 brachytherapy alone. The median follow up period was 62 months（range, 30 to 126 months）. The rate of Grade 1 and 2 rectal bleeding were 5％ and 2.5％. But no Grade 3 or severe bleeding was observed. Risk factors for rectal bleeding were RV100≥0.5 ml. The RV100 should be kept below 0.5 ml.